key: cord-0428889-24ym88yg
authors: Denzler, A.; Jacobs, M. L.; Witte, V.; Schnitzler, P.; Denkinger, C. M.; Knop, M.
title: Rapid comparative evaluation of SARS-CoV-2 rapid point-of-care antigen tests
date: 2021-08-01
journal: nan
DOI: 10.1101/2021.07.29.21261314
sha: 41d0b24a930b195ac6b42b375c6ce17d110a80b3
doc_id: 428889
cord_uid: 24ym88yg

Background: Currently, more than 500 different AgPOCTs for SARS-CoV-2 diagnostics are on sale, for many of which no data about sensitivity other than self-acclaimed values by the manufacturers are available. In many cases these do not reflect real-life diagnostic sensitivities. Therefore, manufacturer-independent quality checks of available AgPOCTs are needed, given the potential implications of false-negative results. Objective: The objective of this study was to develop a scalable approach for direct comparison of the analytical sensitivities of commercially available SARS-CoV-2 antigen point-of-care tests (AgPOCTs) in order to rapidly identify poor performing products. Methods: We present a methodology for quick assessment of the sensitivity of SARS-CoV-2 lateral flow test stripes suitable for quality evaluation of many different products. We established reference samples with high, medium and low SARS-CoV-2 viral loads along with a SARS-CoV-2 negative control sample. Test samples were used to semi-quantitatively assess the analytical sensitivities of 32 different commercial AgPOCTs in a head-to-head comparison. Results: Among 32 SARS-CoV-2 AgPOCTs tested, we observe sensitivity differences across a broad range of viral loads (~7.0*10 to ~1.7*10 SARS-CoV-2 genome copies per ml). 23 AgPOCTs detected the Ct25 test sample (~1.4*10 copies/ ml), while only five tests detected the Ct28 test sample (~1.7*10 copies/ ml). In the low range of analytical sensitivity we found three saliva spit tests only delivering positive results for the Ct21 sample (~2.2*10 copies/ ml). Comparison with published data support our AgPOCT ranking. Importantly, we identified an AgPOCT offered in many local drugstores and supermarkets, which did not reliably recognize the sample with highest viral load (Ct16 test sample with ~7.0*10 copies/ ml) leading to serious doubts in its usefulness in SARS-CoV-2 diagnostics. Conclusion: The rapid sensitivity assessment procedure presented here provides useful estimations on the analytical sensitivities of 32 AgPOCTs and identified a widely-spread AgPOCT with concerningly low sensitivity.

In the SARS-CoV-2 pandemic, lateral-flow antigen tests were developed as a rapid 74 alternative to SARS-CoV-2 reverse transcriptase quantitative polymerase chain 75 reaction (RT-qPCR) based diagnostics. Because of their ease of use, lateral-flow 76 antigen tests are applicable for point-of-care and self testing and can therefore be 77 incorporated in the daily life to support viral containment (WHO, Interim guidance, 78 2020). These tests, in the following referred to as antigen point-of-care tests 79 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 1, 2021. ; https://doi.org/10.1101/2021.07.29.21261314 doi: medRxiv preprint

We tested the analytical sensitivity of a large number of commercially available 124

AgPOCTs by applying pooled samples from nasopharyngeal swabs with defined 125 SARS-CoV2 viral loads including Ct16, Ct21, Ct25 and Ct28 (~7.0*10⁸ to ~1.7*10⁵ 126 genome copies per ml) as well as a pooled sample obtained from SARS-CoV-2 127 negative tested persons. Pools were generated using pseudo-anonymized remnant 128 swab sample material that had been collected for clinical diagnosis of SARS-CoV-2 129 infection by RT-qPCR carried out by the Center for Infectious Diseases, Virology, 130

Heidelberg University Hospital, Germany. Pharyngeal swab specimens were 131 collected through the nose (nasopharyngeal) and contained in viral transport medium 132 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 1, 2021. ; https://doi.org/10.1101/2021.07.29.21261314 doi: medRxiv preprint

We included a total of 32 AgPOCTs available at local supermarkets, pharmacies and 166 drugstores as well as on several online trade platforms (Table 1) . Specific AgPOCTs 167 will be referred to as the respective manufacturer's name (in bold in Table 1 ). The is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 1, 2021. ; https://doi.org/10.1101/2021.07.29.21261314 doi: medRxiv preprint 

In the present study, we sought to establish a standardized procedure to rapidly 179 assess the sensitivities of a large number of SARS-COV-2 AgPOCTs. To this end, 180

we generated a collection of test samples from pooled nasopharyngeal swabs from 181 SARS-CoV-2 positive tested and negative tested individuals. Ct values of the SARS-182

CoV-2 positive pools were determined by RT-qPCR and test samples were prepared 183

accordingly. The test sample collection comprised four SARS-CoV-2 positive pools 184

with defined viral loads (Ct16, Ct21, Ct25, Ct28) and one SARS-CoV-2 negative pool. 185

Per test sample, >200 aliquots with 120 µł sample volume each were prepared, 186 allowing a quick and standardized evaluation of the analytical sensitivities of a large 187 number of different AgPOCTs. 188

We estimated that our test sample collection covers a range from ~7.0*10⁸ (Ct=16) to 189 ~1.7*10⁵ (Ct=28) SARS-CoV-2 genome copies per ml (Supplemental Table S4 ). We 190 qualitatively validated our test sample collection using the LumiraDx SARS-CoV-2 Ag 191 Test device, which was shown to have a high analytical sensitivity (Krüger et al., 192 2021 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 1, 2021. ; https://doi.org/10.1101/2021.07.29.21261314 doi: medRxiv preprint

We tested a total of 32 AgPOCTs (Table 1) these values (T/C ratio) was determined ( Figure 1A ). In addition, we scored a binary 208 (positive or negative) test result using visual inspection of the images by four different 209 persons ( Figure 1B) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 1, 2021. ; https://doi.org/10.1101/2021.07.29.21261314 doi: medRxiv preprint by the fact that the visual assessment was conducted using color vision, while for T/C 223 quantification grayscale images were used. We also observed a large coefficient of 224 variation for some of the tests, in particular for samples with very small T/C ratios, 225 emphasizing weak signals close to the detection limit of the digital quantification 226 (Supplemental Figure S1) . 227

We grouped the tested AgPOCT into categories with low (Group III), medium (Group 228 II) and high (Group I) sensitivity based on the reliability to detect a given SARS-CoV-229 2 positive sample. A sample was considered reliably detected by a given AgPOCT 230 when all or the majority of replicates (at least two out of three or three out of four 231 replicates) of a given sample were scored positive. If none or the minority of 232

replicates of a given sample was detected by the corresponding AgPOCT, reliability 233 requirements were not met. 234

One exception was Lepu Medical, which did not fulfill the requirements for any of 235 these groups. For Group III with lowest sensitivity the minimum criterion was to 236

reliably detect the Ct21 sample and Lepu medical did not even reliably score positive 237 with the Ct16 sample (~7.0*10⁸ copies/ ml). To investigate this product further and is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint (Table 1) , which are provided with a considerably larger amount of lysis 251 buffer (500-1000 µl lysis buffer; Figure 1C ) than most other AgPOCTs resulting in an 252

increased dilution of the sample compared to tests for nasal samples, which are 253 provided on average with 320 µl lysis buffer ( Figure 1C ). Therefore, their low 254 performance in this AgPOCT evaluation study needs to be interpreted with caution. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Figure S3 ). All, except möLäb delivered a positive 275 visual result in all three replicates. 276

Taken together, the data presented here demonstrate that the different SARS-CoV-2 277

AgPOCTs available deviate largely in the analytical sensitivity of the lateral flow test 278 stripes and provided buffer systems, corresponding more than two orders of 279 magnitude of viral genome copies per ml (7.0*10⁸ to 1.7*10⁵ ). 280 281

We developed a straight-forward strategy to evaluate the technical sensitivity of 283

AgPOCTs for SARS-CoV-2. Using a set of four SARS-CoV-2 positive reference 284 samples spanning the relevant dynamic range of the typical sensitivity of AgPOCTs 285 (∼1.7*10⁵ to ∼2.2*10⁷ SARS-CoV-2 genome copies per ml) we were able to group 32 286 commercially available products into AgPOCT groups with high, average and low 287 sensitivity (Group I-III). Most importantly, we identified one product that did not detect 288 any of the test samples and therefore is considered not suitable for SARS-CoV-2 289

The majority of tests investigated in this study reliably detected the Ct25 test sample is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 1, 2021. of detection for each AgPOCT using 138 SARS-CoV-2 positive clinical samples with 300 viral loads ranging from 1.9*10⁴ to 1.8*10⁹ genome copies per ml. Among the 301

AgPOCTs also tested in this study, Healgen was found to be most sensitive closely 302 followed by Abbott, SD Biosensor and nal von minden -all with a 95% limit of 303 detection between 2.3 -9.3*10⁶ SARS-COV-2 genomes per swab. In contrast, for 304

RapiGEN a 95% limit of detection more than three orders of magnitudes lower was 305

found. This discrepancy in performance between RapiGEN and the above mentioned 306 products is supported by other studies (Brümmer et al., 2021) . In our analysis, this 307 trend is also reflected even though we cannot resolve the limits of detection in such 308

great detail: For Healgen and nal von minden, detection of the Ct25 sample 309 (~1.4*10⁶ copies/ ml) was robust with all replicates being positively scored. For 310

RapiGEN, Ct25 test sample detection was less reliable and based on the T/C Ct25 , this 311 product is ranked in the lowest quarter among all AgPOCTs investigated. 312

Among the 32 investigated AgPOCTs, we identified four reliably well performing 313

AgPOCTs, which detected the Ct28 sample (~1.7*10⁵ copies/ ml) as SARS-CoV-2 314 positive in all replicates (Group I). These include in ascending order (based on 315 T/C Ct25 ) Medice, MP, Clongene and Watmind. The latter represents the test winner in 316 our study and is also among the best three AgPOCTs out of 122 tested products with is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 1, 2021. ; https://doi.org/10.1101/2021.07.29.21261314 doi: medRxiv preprint visualisation, evidence provided by Scheiblauer and colleagues (2021) suggests that 323 this test is non-functional with 0% sensitivity for all sample panels supporting the low 324 ranking of Joinstar in this study. In our analysis we detected very weak bands for the 325 Ct21 and Ct16 test samples, however, these were considerably weaker than for all 326 other tests suggesting the possibility that latex beads used for visualisation do fail to 327 produce a strong signal. Besides Joinstar, Ritter and Hygisun, both saliva spit tests 328 similar to Joinstar, also showed low sensitivity in our studies. While we could not find 329 independent evaluation studies for these products, both can be found on the BfArM 330 list (as of July 23, 2021; Supplemental Figure S3 ). Among the low ranked AgPOCTs, 331 the sensitivity of Lepu medical was exceptionally low as this AgPOCT failed to deliver 332 a visible positive test result in most replicates, even for the Ct16 sample. In addition 333 to its poor performance in SARS-CoV-2 diagnostics, out of 20 performed Lepu 334 medical tests three tests technically failed, indicated by the absence of the control 335 band. Importantly, this last test is a very popular product in the area where this study 336 was conducted, available at many drugstores and supermarket chains. Of note is 337 also that Lepu medical differs from other AgPOCTs in its design and sample 338 application. Technical failure did not occur in any of the other AgPOCTs, in which the 339 immunochromatography paper is embedded in the common plastic cassettes. 340

Taken together, comparison with published data for some of the investigated 341 products confirmed our results. Therefore, we provide evidence that a rapid 342 assessment of the sensitivity of SARS-CoV-2 AgPOCTs is feasible. 343

It is important to mention that the volume of the lysis buffer provided with each 344

AgPOCT varies between tests of different manufacturers resulting in a 2.6-to 20-fold 345 dilution of the test samples during the procedure ( Figure 1C ). In this study, test 346 results were not corrected for these different dilution factors, because the sample 347 . CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 1, 2021. ; https://doi.org/10.1101/2021.07.29.21261314 doi: medRxiv preprint dilution is an internal property of each test. Additionally, it is important to note that by 348 using the same sample volume for each AgPOCT potential differences in swab 349

properties, such as absorption volume, which affect the diagnostic sensitivity of 350

AgPOCTs, are neglected. However, we note that for tests based on nasal swabs the 351 used volume of 50 ul approximates the quantity absorbed by these swabs (Corman Currently, there are more than 500 different products available for SARS-CoV-2 359 diagnostics, many of which lack independent assessment of their performance. In 360 most cases the clinical sensitivity values provided by the manufacturer (e.g. in Figure  361 1C) are far >90%, however, detailed information on the used specimen collection and 362 viral loads are usually not provided rendering these values largely inconclusive. 363

Considering that individual products use different antibodies in varying amounts with 364 different specificities and affinities sometimes recognizing different proteins in the 365 viral particle with differing abundances, and diverse staining methods, these 366

conspicuously similar values for clinical sensitivity given by the manufacturer are also 367 unlikely. Therefore, an independent, rapid and critical evaluation of AgPOCTs 368 available is required in order to determine the realistic performance of AgPOCT and 369 especially to identify poor performing products. Given the huge number of products 370 available for rapid SARS-CoV-2 diagnostics, in-depth studies evaluating the quality of 371 AgPOCTs in a time-intensive procedure will not be available any time soon for all 372 products available. Here we identify a non-functional product (Lepu medical) for 373 . CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 1, 2021. ; https://doi.org/10.1101/2021.07.29.21261314 doi: medRxiv preprint SARS-CoV-2 diagnostics, which was and still is (as of July 26, 2021) widely present 374 in the region of Heidelberg, Germany, emphasizing the urgent need for AgPOCT 375 products to undergo better and especially faster producer-independent quality 376 control. The procedure presented here involving a reduced test sample collection and 377 minimal labor represents a feasible strategy for prompt evaluation of available 378

AgPOCTs for their usability in SARS-CoV-2 diagnostics. We provide a useful 379 estimation of the limits of detection for the investigated AgPOCTs as the dimensions 380 and trends are comparable to results from much more laborious in-depth studies. 381 Therefore, we suggest this procedure as a rapid alternative to investigate Covid-19 382

AgPOCs in the absence of reliable data that validate the performance of a specific 383 product. 384 . CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 1, 2021. ; https://doi.org/10.1101/2021.07.29.21261314 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 1, 2021. ; https://doi.org/10.1101/2021.07.29.21261314 doi: medRxiv preprint most replicates of a given Ct test sample). (C) Additional information on investigated AgPOCTs: Sensitivities of AgPOCTs according to the corresponding manufacturer's package insert, volumes of provided lysis buffer and the resulting dilution factor for the Ct test samples (V = 50 µl) are given.

. CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 1, 2021. ; https://doi.org/10.1101/2021.07.29.21261314 doi: medRxiv preprint Figure 2 : Representative images of SARS-CoV-2 AgPOCTs lateral flow test stripes treated with corresponding Ct test samples. Contrast settings were optimized for each AgPOCT example image set in order to ensure best visibility of the test bands. AgPOCT example images are arranged (from left top to right bottom) according to the ranking presented in Figure 1 . Red line indicates the limit of reliable detection (see Figure 1A , B).

. CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 1, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 1, 2021. ; https://doi.org/10.1101/2021.07.29.21261314 doi: medRxiv preprint

The Comparative Clinical Performance of Four SARS

Rapid Antigen Tests and Their Correlation to Infectivity In Vitro

Evaluation of accuracy, exclusivity, limit-of-detection and ease-431 of-use of LumiraDxTM Antigen-detecting point-of-care device for

Multicenter evaluation of 435 the PanbioTM COVID-19 rapid antigen-detection test for the diagnosis of SARS

CoV-2 infection

SARS-CoV-2 rapid antigen test : High sensitivity to detect 439 infectious virus

Federal Institute for Vaccines and Biomedicines

Vergleichende Evaluierung der Sensitivität von SARS-CoV-2

Establishment of an evaluation panel for the decentralized 447 technical evaluation of the sensitivity of 31 rapid detection tests for SARS-CoV-2 448 diagnostics

Comparative sensitivity evaluation for 122 CE-marked 451 SARS-CoV-2 antigen rapid tests

Limits and 454 opportunities of sars-cov-2 antigen rapid tests: An experienced-based perspective. 455 Pathogens

Evaluation of Two Rapid Antigenic Tests for the Detection of SARS-CoV-2 458 in Nasopharyngeal Swabs